American Journal of Medical Genetics Part B: Neuropsychiatric Genetics
Published Online: 10 Oct 2006
Mutation screen of the GAD2 gene and association study of alcoholism in three populations
Jaakko Lappalainen 1 2 *,
Henry R. Kranzler 4, Xingguang Luo 1 2, Mikhail Remizov 3, Sofia Pchelina 3, Anastaisa Taraskina 3, Edwin Zvartau 3, Pirkko Räsanen 5, Taru Makikyro 5, Lucia K. Somberg 1 2, John H. Krystal 1 2, Murray B. Stein 6, Joel Gelernter 1 2 E-mail: joel.gelernter@yale.edu | |
1Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 2VA Connecticut Healthcare System, West Haven, Connecticut 3St. Petersburg State Pavlov Medical University, St. Petersburg, Russia 4Department of Psychiatry, University of Connecticut School of Medicine, Farmington, Connecticut 5Department of Psychiatry, University of Oulu, Oulu, Finland 6Department of Psychiatry, University of California, San Diego, California | |
*Correspondence to Jaakko Lappalainen, Yale University, VA Connecticut Healthcare System, Psychiatry 116A2, 950 Campbell Ave, West Haven CT 06516.
Abstract |
Synaptic actions of -amino butyric acid (GABA) have been implicated in many facets of ethanol's effects and risk for alcoholism. We examined whether variation in glutamate decarboxylase-2 (GAD2), a gene encoding for a major enzyme in the synthesis of GABA, contributes to risk of alcohol dependence (AD). We screened GAD2 for sequence variants using dHPLC in a population of 96 individuals. Several single nucleotide polymorphisms (SNPs), including four rare non-synonymous polymorphisms, were identified. Thirteen SNPs located in the GAD2 gene were genotyped in a sample of 113 Russian males with AD and 100 Russian male controls. These analyses revealed a modest association between the functional GAD2 -243 A > G SNP (rs2236418) and AD (allele P = 0.038, genotype P = 0.008). An additional sample of 138 Russian males with AD were genotyped for the GAD2 -243 A > G. These analyses supported an association of this polymorphism with AD (combined sample allele P = 0.038, genotype P = 0.0009). We extended these findings to additional populations: a sample of 538 college students assessed using the AUDIT and a sample of European-American (EA) AD subjects (n = 235) and controls (n = 310). Analyses in these populations did not support a role for GAD2 in alcoholism. In summary, the results of an extensive search for an association of GAD2 with AD suggest that variation in GAD2 is not a major risk factor for AD in EAs. The functional promoter GAD2 -243 A > G variant may influence risk for AD in some populations, or its role may be limited to susceptibility to severe AD |